Astria Therapeutics (ATXS) Amortization of Deferred Charges: 2017-2018
Historic Amortization of Deferred Charges for Astria Therapeutics (ATXS) over the last 2 years, with Dec 2018 value amounting to -$1,000.
- Astria Therapeutics' Amortization of Deferred Charges fell 103.70% to -$1,000 in Q4 2018 from the same period last year, while for Dec 2018 it was $37,000, marking a year-over-year decrease of 76.13%. This contributed to the annual value of $37,000 for FY2018, which is 76.13% down from last year.
- Latest data reveals that Astria Therapeutics reported Amortization of Deferred Charges of -$1,000 as of Q4 2018, which was down 120.00% from $5,000 recorded in Q3 2018.
- Astria Therapeutics' 5-year Amortization of Deferred Charges high stood at $50,000 for Q1 2017, and its period low was -$1,000 during Q4 2018.
- For the 2-year period, Astria Therapeutics' Amortization of Deferred Charges averaged around $24,000, with its median value being $23,500 (2017).
- Data for Astria Therapeutics' Amortization of Deferred Charges shows a maximum YoY slumped of 103.70% (in 2018) over the last 5 years.
- Quarterly analysis of 2 years shows Astria Therapeutics' Amortization of Deferred Charges stood at $27,000 in 2017, then tumbled by 103.70% to -$1,000 in 2018.
- Its last three reported values are -$1,000 in Q4 2018, $5,000 for Q3 2018, and $13,000 during Q2 2018.